Barbara S Wiggins

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4399355/publications.pdf

Version: 2024-02-01

1040018 996954 17 499 9 15 citations g-index h-index papers 17 17 17 947 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation, 2016, 134, e468-e495.	1.6	203
2	Select Drug-Drug Interactions With DirectÂOral Anticoagulants. Journal of the American College of Cardiology, 2020, 75, 1341-1350.	2.8	87
3	Discharge Counseling for Patients with Heart Failure or Myocardial Infarction: A Best Practices Model Developed by Members of the American College of Clinical Pharmacy's Cardiology Practice and Research Network Based on the Hospital to Home (<scp>H</scp> 2 <scp>H</scp>) Initiative. Pharmacotherapy, 2013, 33, 558-580.	2.6	46
4	Recommendations for Managing Drug–Drug Interactions with Statins and HIV Medications. American Journal of Cardiovascular Drugs, 2017, 17, 375-389.	2.2	36
5	Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin. Pharmacotherapy, 2016, 36, e5-7.	2.6	32
6	Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review. Advances in Therapy, 2020, 37, 656-670.	2.9	25
7	High-Impact Articles Related to the Management of Heart Failure: 2008 Update. Pharmacotherapy, 2009, 29, 82-120.	2.6	10
8	Gemfibrozil in Combination with Statinsâ€"Is It Really Contraindicated?. Current Atherosclerosis Reports, 2016, 18, 18.	4.8	10
9	Statinâ€associated muscle symptoms—A review: Individualizing the approach to optimize care. Pharmacotherapy, 2022, 42, 428-438.	2.6	10
10	Cardiovascular Drug Shortages. Annals of Pharmacotherapy, 2014, 48, 1177-1186.	1.9	9
11	Evolocumab: Considerations for the Management of Hyperlipidemia. Current Atherosclerosis Reports, 2018, 20, 17.	4.8	9
12	Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation and Weighing ≥ 120 Kilograms versus 60–120 Kilograms. American Journal of Cardiovascular Drugs, 2021, 21, 545-551.	2.2	8
13	Mortality and Costs Associated with Wearable Cardioverter-defibrillators after Acute Myocardial Infarction: A Retrospective Cohort Analysis of Medicare Claims Data. Journal of Innovations in Cardiac Rhythm Management, 2019, 10, 3866-3873.	0.5	7
14	Key Articles and Guidelines in the Management of Dyslipidemia: 2019 Update. Journal of Pharmacy Practice, 2020, 33, 882-894.	1.0	4
15	Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications. Pharmacotherapy, 2017, 37, 393-400.	2.6	3
16	A Response to: Letter to the Editor Regarding "Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review― Advances in Therapy, 2020, 37, 4046-4048.	2.9	0
17	Human Angiopoietin-like Protein 3/ANGPTL3 Antibodies. Journal of Cardiovascular Pharmacology, 2021, Publish Ahead of Print, e631-e640.	1.9	O